This fast track antibody is not yet fully characterized. It is subject to these terms and conditions

Overview

  • Product name
  • Description
    Goat polyclonal to PMS1

    This product is a fast track antibody. It has been affinity purified and shows high titre values against the immunizing peptide by ELISA. Read the terms of use »

  • Species reactivity

    Predicted to work with: Human
  • Immunogen

    Peptide with sequence RPFFHHLTYLPETT, from C Terminus of the protein sequence according to NP_000525.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    Tris saline, 0.02% Na azide, pH7.3 with 0.5% BSA
  • Concentration information loading...
  • Purity
    IgG fraction
  • Purification notes
    Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Fast track antibodies constitute a diverse group of products that have been released to accelerate your research, but are not yet fully characterized. They have all been affinity purified and show high titre values against the immunizing peptide (by ELISA). Fast track terms of use

Application Abreviews Notes
WB Use at an assay dependent concentration. Predicted molecular weight: 106 kDa.

No signal obtained yet but low background observed in Human Brain and Kidney extracts at up to 2µg/ml.

Target

  • Function
    Probably involved in the repair of mismatches in DNA.
  • Involvement in disease
    Defects in PMS1 are the cause of hereditary non-polyposis colorectal cancer type 3 (HNPCC3) [MIM:600258]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
  • Sequence similarities
    Belongs to the DNA mismatch repair mutL/hexB family.
    Contains 1 HMG box DNA-binding domain.
  • Cellular localization
    Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • DNA mismatch repair protein PMS1 antibody
    • FLJ98259 antibody
    • HNPCC3 antibody
    • hPMS1 antibody
    • Human homolog of yeast mutL antibody
    • Mismatch repair gene PMSL1 antibody
    • pms1 antibody
    • PMS1 postmeiotic segregation increased 1 (S. cerevisiae) antibody
    • PMS1 postmeiotic segregation increased 1 antibody
    • PMS1 protein homolog 1 antibody
    • PMS1_HUMAN antibody
    • PMSL1 antibody
    • Rhabdomyosarcoma antigen MU RMS 40.10B antibody
    • Rhabdomyosarcoma antigen MU RMS 40.10E antibody
    see all

References

ab3818 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab3818.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up